VCEL - Vericel Corporation
| Previous Close | 11.50 |
| Open | 11.35 |
| Bid | 11.05 x 900 |
| Ask | 11.30 x 2900 |
| Day's Range | 10.85 - 11.35 |
| 52 Week Range | 3.30 - 14.75 |
| Volume | 65,909 |
| Avg. Volume | 1,249,281 |
| Market Cap | 472.128M |
| Beta | 4.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.44 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.75 |
- Thomson Reuters StreetEvents•12 hours ago
Edited Transcript of VCEL earnings conference call or presentation 6-Aug-18 8:30pm GMT
Q2 2018 Vericel Corp Earnings Call
- GlobeNewswire•11 days ago
Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance
CAMBRIDGE, Mass., Aug. 06, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights ...
- ACCESSWIRE•11 days ago
Vericel Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Vericel Corporation (NASDAQ: VCEL ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. ...
- Benzinga•11 days ago
Vericel's Earnings Preview
Vericel (NASDAQ: VCEL ) announces its next round of earnings this Monday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement. Earnings and Revenue Analysts are expecting ...
- GlobeNewswire•22 days ago
Vericel to Present at the 38th Annual Canaccord Genuity Growth Conference
CAMBRIDGE, Mass., July 26, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, ...
- ACCESSWIRE•23 days ago
Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks
Stock Research Monitor: TPIV, VCEL, and VRTX LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on VKTX sign up now at www.wallstequities.com/registration . On Tuesday, July 24, ...
- GlobeNewswire•25 days ago
Vericel to Report Second-Quarter 2018 Financial Results on August 6, 2018
CAMBRIDGE, Mass., July 23, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call ...
- ACCESSWIRE•last month
3 Biotech Stocks to Bet on in the Second Half of 2018
Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential. HENDERSON, NV / ACCESSWIRE ...
- GlobeNewswire•2 months ago
Vericel Added to Russell 3000® Index
CAMBRIDGE, Mass., June 25, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it has been added to the Russell 3000 ...
- Simply Wall St.•2 months ago
When Will Vericel Corporation (NASDAQ:VCEL) Turn A Profit?
Vericel Corporation’s (NASDAQ:VCEL): Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. With the latestRead More...
- GlobeNewswire•2 months ago
Vericel Corporation Announces Closing of $74.8 Million Public Offering and Full Exercise of The Underwriters’ Option to Purchase Additional Shares
Leerink Partners acted as the lead bookrunner for the offering. BTIG, LLC also acted as a bookrunner. Ladenburg Thalmann acted as co-manager. The securities described above were offered by Vericel pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities Exchange Commission (SEC) on June 29, 2015 and declared effective by the SEC on July 15, 2015. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement for the offering was filed with the SEC on June 1, 2018, and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by contacting Leerink Partners LLC, c/o Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at syndicate@leerink.com, or by phone at (800) 808-7525, ext. 6132 or by contacting BTIG, LLC at 825 Third Avenue, 6th Floor, New York, NY, 10022, or by telephone at (212) 593-7555 or by e-mail at equitycapitalmarkets@btig.com.
- ACCESSWIRE•2 months ago
Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks
Shares in Needham, Massachusetts headquartered Verastem Inc. saw a decline of 3.56%, ending Monday's trading session at $5.14. The stock recorded a trading volume of 2.58 million shares, which was higher than its three months average volume of 1.23 million shares.
- GlobeNewswire•3 months ago
Vericel Corporation Prices $65 Million Public Offering of Common Stock
CAMBRIDGE, Mass., May 31, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the pricing of its previously announced underwritten ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of VCEL earnings conference call or presentation 8-May-18 12:30pm GMT
Q1 2018 Vericel Corp Earnings Call
- GlobeNewswire•3 months ago
Vericel Corporation Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., May 30, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it intends to offer and sell, subject ...
- GlobeNewswire•3 months ago
Vericel to Present at the Jefferies 2018 Global Healthcare Conference
CAMBRIDGE, Mass., May 25, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will ...
- Yahoo Finance•3 months ago
What this year's top fund managers are doing to smoke the competition
As big names have treaded water, the best performing funds have feasted in market famine thanks to little-known healthcare and technology companies.
Yahoo Finance•3 months agoAmerica's top fund is run by a father-son duo from the shores of Lake Minnetonka
The best performing mutual fund so far this year - beating the S&P 500 by more than 20% - is run by a small-town duo of father and son.
- Investopedia•4 months ago
Vericel Stock Looks to Break Out From Prior Highs
Vericel shares are retesting their prior highs following positive analyst commentary.
- Zacks•4 months ago
Will Vericel (VCEL) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Vericel Corporation (VCEL).
